nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA7—colon cancer	0.296	0.572	CbGaD
Nilotinib—BRAF—colon cancer	0.187	0.361	CbGaD
Nilotinib—UGT1A1—Irinotecan—colon cancer	0.0355	0.211	CbGbCtD
Nilotinib—ABCB1—colon cancer	0.0346	0.0668	CbGaD
Nilotinib—ABCG2—Irinotecan—colon cancer	0.0195	0.116	CbGbCtD
Nilotinib—ABCG2—Fluorouracil—colon cancer	0.0188	0.111	CbGbCtD
Nilotinib—ABCG2—Vincristine—colon cancer	0.0171	0.101	CbGbCtD
Nilotinib—CYP2B6—Irinotecan—colon cancer	0.0137	0.0815	CbGbCtD
Nilotinib—CYP2C9—Capecitabine—colon cancer	0.0118	0.0697	CbGbCtD
Nilotinib—ABCG2—Methotrexate—colon cancer	0.0103	0.0614	CbGbCtD
Nilotinib—CYP2C8—Fluorouracil—colon cancer	0.00999	0.0593	CbGbCtD
Nilotinib—ABCB1—Irinotecan—colon cancer	0.00705	0.0418	CbGbCtD
Nilotinib—CYP2C9—Fluorouracil—colon cancer	0.00697	0.0413	CbGbCtD
Nilotinib—ABCB1—Vincristine—colon cancer	0.00616	0.0365	CbGbCtD
Nilotinib—CYP3A4—Irinotecan—colon cancer	0.00422	0.025	CbGbCtD
Nilotinib—ABCB1—Methotrexate—colon cancer	0.00373	0.0221	CbGbCtD
Nilotinib—CYP3A4—Vincristine—colon cancer	0.00369	0.0219	CbGbCtD
Nilotinib—KIT—myenteric nerve plexus—colon cancer	0.00294	0.037	CbGeAlD
Nilotinib—Ponatinib—FGFR3—colon cancer	0.00224	0.451	CrCbGaD
Nilotinib—ABL1—Topotecan—Irinotecan—colon cancer	0.00182	1	CbGdCrCtD
Nilotinib—MAPK8—endothelium—colon cancer	0.00156	0.0197	CbGeAlD
Nilotinib—MAPK8—blood vessel—colon cancer	0.00144	0.0181	CbGeAlD
Nilotinib—TIE1—endothelium—colon cancer	0.00135	0.0171	CbGeAlD
Nilotinib—TIE1—blood vessel—colon cancer	0.00125	0.0157	CbGeAlD
Nilotinib—Imatinib—CA7—colon cancer	0.00122	0.246	CrCbGaD
Nilotinib—Ponatinib—SRC—colon cancer	0.00113	0.228	CrCbGaD
Nilotinib—EPHB4—endothelium—colon cancer	0.00094	0.0118	CbGeAlD
Nilotinib—MAPK14—blood vessel—colon cancer	0.000914	0.0115	CbGeAlD
Nilotinib—TEK—endothelium—colon cancer	0.000899	0.0113	CbGeAlD
Nilotinib—CA9—gall bladder—colon cancer	0.000882	0.0111	CbGeAlD
Nilotinib—EPHB4—blood vessel—colon cancer	0.000867	0.0109	CbGeAlD
Nilotinib—MAPK8—embryo—colon cancer	0.000859	0.0108	CbGeAlD
Nilotinib—FRK—renal system—colon cancer	0.000852	0.0107	CbGeAlD
Nilotinib—EPHA2—blood vessel—colon cancer	0.00085	0.0107	CbGeAlD
Nilotinib—TEK—blood vessel—colon cancer	0.00083	0.0104	CbGeAlD
Nilotinib—CDC42BPB—smooth muscle tissue—colon cancer	0.000747	0.00941	CbGeAlD
Nilotinib—CDC42BPB—renal system—colon cancer	0.000719	0.00905	CbGeAlD
Nilotinib—EPHB3—embryo—colon cancer	0.000708	0.00892	CbGeAlD
Nilotinib—FRK—lymphoid tissue—colon cancer	0.000708	0.00892	CbGeAlD
Nilotinib—PDGFRA—gall bladder—colon cancer	0.000707	0.00891	CbGeAlD
Nilotinib—MAPK8—epithelium—colon cancer	0.000701	0.00883	CbGeAlD
Nilotinib—BLK—lymphoid tissue—colon cancer	0.000683	0.0086	CbGeAlD
Nilotinib—MAPK8—smooth muscle tissue—colon cancer	0.000675	0.00851	CbGeAlD
Nilotinib—EPHB2—lymphoid tissue—colon cancer	0.000675	0.0085	CbGeAlD
Nilotinib—EPHB2—digestive system—colon cancer	0.000667	0.0084	CbGeAlD
Nilotinib—KIT—endothelium—colon cancer	0.000651	0.00821	CbGeAlD
Nilotinib—MAPK8—renal system—colon cancer	0.00065	0.00819	CbGeAlD
Nilotinib—TIE1—epithelium—colon cancer	0.000608	0.00765	CbGeAlD
Nilotinib—KIT—blood vessel—colon cancer	0.000601	0.00757	CbGeAlD
Nilotinib—EPHA4—embryo—colon cancer	0.000592	0.00745	CbGeAlD
Nilotinib—CDC42BPB—digestive system—colon cancer	0.00059	0.00743	CbGeAlD
Nilotinib—PDGFRB—blood vessel—colon cancer	0.000587	0.00739	CbGeAlD
Nilotinib—TIE1—smooth muscle tissue—colon cancer	0.000585	0.00738	CbGeAlD
Nilotinib—KIT—gall bladder—colon cancer	0.000565	0.00712	CbGeAlD
Nilotinib—PDGFRB—gall bladder—colon cancer	0.000552	0.00696	CbGeAlD
Nilotinib—MAPK14—embryo—colon cancer	0.000545	0.00687	CbGeAlD
Nilotinib—FGR—embryo—colon cancer	0.000543	0.00684	CbGeAlD
Nilotinib—MAPK8—lymphoid tissue—colon cancer	0.00054	0.0068	CbGeAlD
Nilotinib—MAPK8—digestive system—colon cancer	0.000533	0.00672	CbGeAlD
Nilotinib—FRK—liver—colon cancer	0.000521	0.00656	CbGeAlD
Nilotinib—CDC42BPB—vagina—colon cancer	0.000521	0.00656	CbGeAlD
Nilotinib—LYN—lymphoid tissue—colon cancer	0.000498	0.00627	CbGeAlD
Nilotinib—TEK—embryo—colon cancer	0.000495	0.00623	CbGeAlD
Nilotinib—MAPK8—bone marrow—colon cancer	0.000491	0.00619	CbGeAlD
Nilotinib—MAP4K1—lymphoid tissue—colon cancer	0.000491	0.00618	CbGeAlD
Nilotinib—CA7—renal system—colon cancer	0.000482	0.00607	CbGeAlD
Nilotinib—MAPK8—vagina—colon cancer	0.000471	0.00593	CbGeAlD
Nilotinib—PDGFRA—embryo—colon cancer	0.000448	0.00565	CbGeAlD
Nilotinib—MAP4K1—bone marrow—colon cancer	0.000447	0.00563	CbGeAlD
Nilotinib—MAPK14—epithelium—colon cancer	0.000445	0.00561	CbGeAlD
Nilotinib—EPHB3—digestive system—colon cancer	0.00044	0.00554	CbGeAlD
Nilotinib—CDC42BPB—liver—colon cancer	0.000439	0.00553	CbGeAlD
Nilotinib—MAPK14—smooth muscle tissue—colon cancer	0.000429	0.0054	CbGeAlD
Nilotinib—MAP4K1—vagina—colon cancer	0.000428	0.00539	CbGeAlD
Nilotinib—EPHB4—epithelium—colon cancer	0.000422	0.00531	CbGeAlD
Nilotinib—EPHA2—epithelium—colon cancer	0.000414	0.00521	CbGeAlD
Nilotinib—MAPK14—renal system—colon cancer	0.000413	0.0052	CbGeAlD
Nilotinib—HCK—lymphoid tissue—colon cancer	0.000409	0.00515	CbGeAlD
Nilotinib—BRAF—bone marrow—colon cancer	0.000409	0.00515	CbGeAlD
Nilotinib—EPHB4—smooth muscle tissue—colon cancer	0.000407	0.00512	CbGeAlD
Nilotinib—HCK—digestive system—colon cancer	0.000404	0.00509	CbGeAlD
Nilotinib—TEK—epithelium—colon cancer	0.000404	0.00509	CbGeAlD
Nilotinib—MAPK8—liver—colon cancer	0.000397	0.005	CbGeAlD
Nilotinib—CA7—digestive system—colon cancer	0.000395	0.00498	CbGeAlD
Nilotinib—CSF1R—embryo—colon cancer	0.000395	0.00497	CbGeAlD
Nilotinib—BRAF—vagina—colon cancer	0.000391	0.00493	CbGeAlD
Nilotinib—EPHB4—renal system—colon cancer	0.000391	0.00493	CbGeAlD
Nilotinib—TEK—smooth muscle tissue—colon cancer	0.000389	0.0049	CbGeAlD
Nilotinib—EPHB3—vagina—colon cancer	0.000388	0.00489	CbGeAlD
Nilotinib—BLK—lymph node—colon cancer	0.000385	0.00485	CbGeAlD
Nilotinib—TEK—renal system—colon cancer	0.000375	0.00472	CbGeAlD
Nilotinib—HCK—bone marrow—colon cancer	0.000372	0.00469	CbGeAlD
Nilotinib—LYN—liver—colon cancer	0.000367	0.00462	CbGeAlD
Nilotinib—KIT—embryo—colon cancer	0.000358	0.00451	CbGeAlD
Nilotinib—HCK—vagina—colon cancer	0.000357	0.00449	CbGeAlD
Nilotinib—ABL2—vagina—colon cancer	0.000355	0.00447	CbGeAlD
Nilotinib—PDGFRA—smooth muscle tissue—colon cancer	0.000352	0.00444	CbGeAlD
Nilotinib—PDGFRB—embryo—colon cancer	0.00035	0.00441	CbGeAlD
Nilotinib—CA9—digestive system—colon cancer	0.000347	0.00437	CbGeAlD
Nilotinib—TIE1—liver—colon cancer	0.000344	0.00434	CbGeAlD
Nilotinib—MAPK14—lymphoid tissue—colon cancer	0.000343	0.00432	CbGeAlD
Nilotinib—FGR—lymphoid tissue—colon cancer	0.000341	0.0043	CbGeAlD
Nilotinib—MAPK11—lymph node—colon cancer	0.00034	0.00428	CbGeAlD
Nilotinib—PDGFRA—renal system—colon cancer	0.000339	0.00427	CbGeAlD
Nilotinib—MAPK14—digestive system—colon cancer	0.000339	0.00427	CbGeAlD
Nilotinib—FGR—digestive system—colon cancer	0.000337	0.00425	CbGeAlD
Nilotinib—CDC42BPB—lymph node—colon cancer	0.000337	0.00424	CbGeAlD
Nilotinib—CA2—gall bladder—colon cancer	0.000335	0.00422	CbGeAlD
Nilotinib—CA3—bone marrow—colon cancer	0.000334	0.00421	CbGeAlD
Nilotinib—BRAF—liver—colon cancer	0.00033	0.00416	CbGeAlD
Nilotinib—EPHA4—vagina—colon cancer	0.000324	0.00409	CbGeAlD
Nilotinib—UGT1A1—renal system—colon cancer	0.000324	0.00408	CbGeAlD
Nilotinib—EPHB4—digestive system—colon cancer	0.000321	0.00404	CbGeAlD
Nilotinib—CA3—vagina—colon cancer	0.00032	0.00404	CbGeAlD
Nilotinib—EPHA3—lymph node—colon cancer	0.000319	0.00402	CbGeAlD
Nilotinib—EPHA2—lymphoid tissue—colon cancer	0.000319	0.00402	CbGeAlD
Nilotinib—EPHA2—digestive system—colon cancer	0.000315	0.00397	CbGeAlD
Nilotinib—CA12—renal system—colon cancer	0.000313	0.00395	CbGeAlD
Nilotinib—MAPK14—bone marrow—colon cancer	0.000312	0.00393	CbGeAlD
Nilotinib—ABL1—embryo—colon cancer	0.000312	0.00393	CbGeAlD
Nilotinib—TEK—lymphoid tissue—colon cancer	0.000311	0.00392	CbGeAlD
Nilotinib—FGR—bone marrow—colon cancer	0.000311	0.00392	CbGeAlD
Nilotinib—LCK—bone marrow—colon cancer	0.000311	0.00392	CbGeAlD
Nilotinib—CSF1R—smooth muscle tissue—colon cancer	0.00031	0.00391	CbGeAlD
Nilotinib—MAPK8—lymph node—colon cancer	0.000305	0.00384	CbGeAlD
Nilotinib—HCK—liver—colon cancer	0.000301	0.00379	CbGeAlD
Nilotinib—ABL2—liver—colon cancer	0.000299	0.00377	CbGeAlD
Nilotinib—MAPK14—vagina—colon cancer	0.000299	0.00377	CbGeAlD
Nilotinib—LCK—vagina—colon cancer	0.000298	0.00375	CbGeAlD
Nilotinib—FGR—vagina—colon cancer	0.000298	0.00375	CbGeAlD
Nilotinib—EPHB4—bone marrow—colon cancer	0.000296	0.00373	CbGeAlD
Nilotinib—KIT—epithelium—colon cancer	0.000292	0.00368	CbGeAlD
Nilotinib—PDGFRB—epithelium—colon cancer	0.000286	0.0036	CbGeAlD
Nilotinib—EPHB4—vagina—colon cancer	0.000283	0.00357	CbGeAlD
Nilotinib—KIT—smooth muscle tissue—colon cancer	0.000282	0.00355	CbGeAlD
Nilotinib—PDGFRA—lymphoid tissue—colon cancer	0.000282	0.00355	CbGeAlD
Nilotinib—PDGFRA—digestive system—colon cancer	0.000278	0.00351	CbGeAlD
Nilotinib—EPHA2—vagina—colon cancer	0.000278	0.0035	CbGeAlD
Nilotinib—MAP4K1—lymph node—colon cancer	0.000277	0.00349	CbGeAlD
Nilotinib—PDGFRB—smooth muscle tissue—colon cancer	0.000275	0.00347	CbGeAlD
Nilotinib—KIT—renal system—colon cancer	0.000271	0.00342	CbGeAlD
Nilotinib—CA3—liver—colon cancer	0.00027	0.0034	CbGeAlD
Nilotinib—UGT1A1—digestive system—colon cancer	0.000265	0.00334	CbGeAlD
Nilotinib—PDGFRB—renal system—colon cancer	0.000265	0.00334	CbGeAlD
Nilotinib—TIE1—lymph node—colon cancer	0.000264	0.00333	CbGeAlD
Nilotinib—EPHB6—vagina—colon cancer	0.000259	0.00327	CbGeAlD
Nilotinib—CA12—digestive system—colon cancer	0.000257	0.00324	CbGeAlD
Nilotinib—BRAF—lymph node—colon cancer	0.000253	0.00319	CbGeAlD
Nilotinib—MAPK14—liver—colon cancer	0.000252	0.00318	CbGeAlD
Nilotinib—FGR—liver—colon cancer	0.000251	0.00316	CbGeAlD
Nilotinib—LCK—liver—colon cancer	0.000251	0.00316	CbGeAlD
Nilotinib—EPHB3—lymph node—colon cancer	0.000251	0.00316	CbGeAlD
Nilotinib—CA1—renal system—colon cancer	0.000248	0.00313	CbGeAlD
Nilotinib—CSF1R—lymphoid tissue—colon cancer	0.000248	0.00312	CbGeAlD
Nilotinib—PDGFRA—vagina—colon cancer	0.000246	0.0031	CbGeAlD
Nilotinib—CA14—liver—colon cancer	0.000245	0.00309	CbGeAlD
Nilotinib—ABL1—smooth muscle tissue—colon cancer	0.000245	0.00309	CbGeAlD
Nilotinib—CSF1R—digestive system—colon cancer	0.000245	0.00309	CbGeAlD
Nilotinib—EPHB4—liver—colon cancer	0.000239	0.00301	CbGeAlD
Nilotinib—ABL1—renal system—colon cancer	0.000236	0.00297	CbGeAlD
Nilotinib—EPHA2—liver—colon cancer	0.000235	0.00296	CbGeAlD
Nilotinib—Ponatinib—ABCB1—colon cancer	0.000232	0.0466	CrCbGaD
Nilotinib—HCK—lymph node—colon cancer	0.000231	0.00291	CbGeAlD
Nilotinib—ABL2—lymph node—colon cancer	0.000229	0.00289	CbGeAlD
Nilotinib—TEK—liver—colon cancer	0.000229	0.00288	CbGeAlD
Nilotinib—CSF1R—bone marrow—colon cancer	0.000226	0.00285	CbGeAlD
Nilotinib—KIT—lymphoid tissue—colon cancer	0.000225	0.00284	CbGeAlD
Nilotinib—KIT—digestive system—colon cancer	0.000222	0.0028	CbGeAlD
Nilotinib—MAP2K5—vagina—colon cancer	0.000222	0.00279	CbGeAlD
Nilotinib—PDGFRB—lymphoid tissue—colon cancer	0.00022	0.00277	CbGeAlD
Nilotinib—PDGFRB—digestive system—colon cancer	0.000217	0.00274	CbGeAlD
Nilotinib—CSF1R—vagina—colon cancer	0.000216	0.00273	CbGeAlD
Nilotinib—CA2—embryo—colon cancer	0.000212	0.00268	CbGeAlD
Nilotinib—EPHA4—lymph node—colon cancer	0.00021	0.00264	CbGeAlD
Nilotinib—PDGFRA—liver—colon cancer	0.000207	0.00261	CbGeAlD
Nilotinib—CA3—lymph node—colon cancer	0.000207	0.00261	CbGeAlD
Nilotinib—CA1—lymphoid tissue—colon cancer	0.000206	0.0026	CbGeAlD
Nilotinib—KIT—bone marrow—colon cancer	0.000205	0.00258	CbGeAlD
Nilotinib—CA1—digestive system—colon cancer	0.000203	0.00256	CbGeAlD
Nilotinib—PDGFRB—bone marrow—colon cancer	0.0002	0.00252	CbGeAlD
Nilotinib—UGT1A1—liver—colon cancer	0.000198	0.00249	CbGeAlD
Nilotinib—KIT—vagina—colon cancer	0.000196	0.00248	CbGeAlD
Nilotinib—ABL1—lymphoid tissue—colon cancer	0.000196	0.00247	CbGeAlD
Nilotinib—CA4—renal system—colon cancer	0.000194	0.00244	CbGeAlD
Nilotinib—ABL1—digestive system—colon cancer	0.000194	0.00244	CbGeAlD
Nilotinib—MAPK14—lymph node—colon cancer	0.000193	0.00244	CbGeAlD
Nilotinib—FGR—lymph node—colon cancer	0.000193	0.00243	CbGeAlD
Nilotinib—LCK—lymph node—colon cancer	0.000193	0.00243	CbGeAlD
Nilotinib—PDGFRB—vagina—colon cancer	0.000192	0.00242	CbGeAlD
Nilotinib—CA1—bone marrow—colon cancer	0.000188	0.00236	CbGeAlD
Nilotinib—MAP2K5—liver—colon cancer	0.000187	0.00236	CbGeAlD
Nilotinib—EPHB4—lymph node—colon cancer	0.000183	0.00231	CbGeAlD
Nilotinib—CSF1R—liver—colon cancer	0.000183	0.0023	CbGeAlD
Nilotinib—EPHA2—lymph node—colon cancer	0.00018	0.00227	CbGeAlD
Nilotinib—ABL1—bone marrow—colon cancer	0.000179	0.00225	CbGeAlD
Nilotinib—TEK—lymph node—colon cancer	0.000175	0.00221	CbGeAlD
Nilotinib—CA2—epithelium—colon cancer	0.000173	0.00218	CbGeAlD
Nilotinib—ABL1—vagina—colon cancer	0.000171	0.00215	CbGeAlD
Nilotinib—EPHB6—lymph node—colon cancer	0.000168	0.00211	CbGeAlD
Nilotinib—CA2—smooth muscle tissue—colon cancer	0.000167	0.0021	CbGeAlD
Nilotinib—KIT—liver—colon cancer	0.000166	0.00209	CbGeAlD
Nilotinib—ABCB1—blood vessel—colon cancer	0.000163	0.00205	CbGeAlD
Nilotinib—PDGFRB—liver—colon cancer	0.000162	0.00204	CbGeAlD
Nilotinib—CA2—renal system—colon cancer	0.000161	0.00203	CbGeAlD
Nilotinib—CA4—digestive system—colon cancer	0.000159	0.002	CbGeAlD
Nilotinib—PDGFRA—lymph node—colon cancer	0.000159	0.002	CbGeAlD
Nilotinib—CYP2C8—renal system—colon cancer	0.000153	0.00193	CbGeAlD
Nilotinib—CA1—liver—colon cancer	0.000152	0.00191	CbGeAlD
Nilotinib—CA4—bone marrow—colon cancer	0.000147	0.00185	CbGeAlD
Nilotinib—ABL1—liver—colon cancer	0.000144	0.00182	CbGeAlD
Nilotinib—MAP2K5—lymph node—colon cancer	0.000143	0.00181	CbGeAlD
Nilotinib—Imatinib—ABCB1—colon cancer	0.000143	0.0287	CrCbGaD
Nilotinib—CSF1R—lymph node—colon cancer	0.00014	0.00176	CbGeAlD
Nilotinib—CYP2B6—renal system—colon cancer	0.000137	0.00173	CbGeAlD
Nilotinib—CA2—lymphoid tissue—colon cancer	0.000134	0.00168	CbGeAlD
Nilotinib—CA2—digestive system—colon cancer	0.000132	0.00166	CbGeAlD
Nilotinib—KIT—lymph node—colon cancer	0.000127	0.0016	CbGeAlD
Nilotinib—PDGFRB—lymph node—colon cancer	0.000124	0.00156	CbGeAlD
Nilotinib—CA2—bone marrow—colon cancer	0.000122	0.00153	CbGeAlD
Nilotinib—CA2—vagina—colon cancer	0.000116	0.00147	CbGeAlD
Nilotinib—CA1—lymph node—colon cancer	0.000116	0.00146	CbGeAlD
Nilotinib—CYP2B6—lymphoid tissue—colon cancer	0.000114	0.00144	CbGeAlD
Nilotinib—CYP2B6—digestive system—colon cancer	0.000113	0.00142	CbGeAlD
Nilotinib—ABCG2—bone marrow—colon cancer	0.000113	0.00142	CbGeAlD
Nilotinib—CYP2C9—digestive system—colon cancer	0.000112	0.00141	CbGeAlD
Nilotinib—CYP2C8—vagina—colon cancer	0.000111	0.0014	CbGeAlD
Nilotinib—ABL1—lymph node—colon cancer	0.000111	0.00139	CbGeAlD
Nilotinib—ABCG2—vagina—colon cancer	0.000108	0.00136	CbGeAlD
Nilotinib—Hepatobiliary disease—Capecitabine—colon cancer	0.000104	0.00112	CcSEcCtD
Nilotinib—Epistaxis—Capecitabine—colon cancer	0.000104	0.00112	CcSEcCtD
Nilotinib—CYP3A4—renal system—colon cancer	0.000104	0.00131	CbGeAlD
Nilotinib—Discomfort—Fluorouracil—colon cancer	0.000104	0.00111	CcSEcCtD
Nilotinib—Shock—Irinotecan—colon cancer	0.000103	0.00111	CcSEcCtD
Nilotinib—Nervous system disorder—Irinotecan—colon cancer	0.000103	0.00111	CcSEcCtD
Nilotinib—Thrombocytopenia—Irinotecan—colon cancer	0.000103	0.0011	CcSEcCtD
Nilotinib—Anorexia—Vincristine—colon cancer	0.000103	0.0011	CcSEcCtD
Nilotinib—CYP2D6—renal system—colon cancer	0.000102	0.00129	CbGeAlD
Nilotinib—Hyperhidrosis—Irinotecan—colon cancer	0.000101	0.00109	CcSEcCtD
Nilotinib—Confusional state—Fluorouracil—colon cancer	0.000101	0.00109	CcSEcCtD
Nilotinib—Hypotension—Vincristine—colon cancer	0.000101	0.00108	CcSEcCtD
Nilotinib—Bradycardia—Capecitabine—colon cancer	0.000101	0.00108	CcSEcCtD
Nilotinib—Oedema—Fluorouracil—colon cancer	0.0001	0.00108	CcSEcCtD
Nilotinib—Anorexia—Irinotecan—colon cancer	0.0001	0.00107	CcSEcCtD
Nilotinib—Infection—Fluorouracil—colon cancer	9.98e-05	0.00107	CcSEcCtD
Nilotinib—CYP2B6—vagina—colon cancer	9.95e-05	0.00125	CbGeAlD
Nilotinib—Haemoglobin—Capecitabine—colon cancer	9.93e-05	0.00107	CcSEcCtD
Nilotinib—Rhinitis—Capecitabine—colon cancer	9.91e-05	0.00106	CcSEcCtD
Nilotinib—Haemorrhage—Capecitabine—colon cancer	9.88e-05	0.00106	CcSEcCtD
Nilotinib—Hepatitis—Capecitabine—colon cancer	9.88e-05	0.00106	CcSEcCtD
Nilotinib—Nervous system disorder—Fluorouracil—colon cancer	9.86e-05	0.00106	CcSEcCtD
Nilotinib—Thrombocytopenia—Fluorouracil—colon cancer	9.84e-05	0.00106	CcSEcCtD
Nilotinib—Hypoaesthesia—Capecitabine—colon cancer	9.83e-05	0.00106	CcSEcCtD
Nilotinib—CA2—liver—colon cancer	9.83e-05	0.00124	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Vincristine—colon cancer	9.82e-05	0.00105	CcSEcCtD
Nilotinib—Pharyngitis—Capecitabine—colon cancer	9.81e-05	0.00105	CcSEcCtD
Nilotinib—Tachycardia—Fluorouracil—colon cancer	9.81e-05	0.00105	CcSEcCtD
Nilotinib—Hypotension—Irinotecan—colon cancer	9.8e-05	0.00105	CcSEcCtD
Nilotinib—Urinary tract disorder—Capecitabine—colon cancer	9.76e-05	0.00105	CcSEcCtD
Nilotinib—Insomnia—Vincristine—colon cancer	9.74e-05	0.00105	CcSEcCtD
Nilotinib—Oedema peripheral—Capecitabine—colon cancer	9.74e-05	0.00105	CcSEcCtD
Nilotinib—Connective tissue disorder—Capecitabine—colon cancer	9.71e-05	0.00104	CcSEcCtD
Nilotinib—ABCB1—embryo—colon cancer	9.7e-05	0.00122	CbGeAlD
Nilotinib—Urethral disorder—Capecitabine—colon cancer	9.69e-05	0.00104	CcSEcCtD
Nilotinib—Paraesthesia—Vincristine—colon cancer	9.67e-05	0.00104	CcSEcCtD
Nilotinib—Breast disorder—Methotrexate—colon cancer	9.61e-05	0.00103	CcSEcCtD
Nilotinib—Anorexia—Fluorouracil—colon cancer	9.58e-05	0.00103	CcSEcCtD
Nilotinib—Visual impairment—Capecitabine—colon cancer	9.53e-05	0.00102	CcSEcCtD
Nilotinib—Insomnia—Irinotecan—colon cancer	9.49e-05	0.00102	CcSEcCtD
Nilotinib—Paraesthesia—Irinotecan—colon cancer	9.42e-05	0.00101	CcSEcCtD
Nilotinib—Hypotension—Fluorouracil—colon cancer	9.39e-05	0.00101	CcSEcCtD
Nilotinib—Decreased appetite—Vincristine—colon cancer	9.37e-05	0.00101	CcSEcCtD
Nilotinib—CYP2C8—liver—colon cancer	9.36e-05	0.00118	CbGeAlD
Nilotinib—Dyspnoea—Irinotecan—colon cancer	9.35e-05	0.00101	CcSEcCtD
Nilotinib—Erythema multiforme—Capecitabine—colon cancer	9.35e-05	0.001	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Vincristine—colon cancer	9.3e-05	0.000999	CcSEcCtD
Nilotinib—Fatigue—Vincristine—colon cancer	9.29e-05	0.000998	CcSEcCtD
Nilotinib—Eye disorder—Capecitabine—colon cancer	9.24e-05	0.000992	CcSEcCtD
Nilotinib—Dyspepsia—Irinotecan—colon cancer	9.24e-05	0.000992	CcSEcCtD
Nilotinib—Tinnitus—Capecitabine—colon cancer	9.22e-05	0.00099	CcSEcCtD
Nilotinib—Pain—Vincristine—colon cancer	9.21e-05	0.00099	CcSEcCtD
Nilotinib—Constipation—Vincristine—colon cancer	9.21e-05	0.00099	CcSEcCtD
Nilotinib—Cardiac disorder—Capecitabine—colon cancer	9.17e-05	0.000986	CcSEcCtD
Nilotinib—Flushing—Capecitabine—colon cancer	9.17e-05	0.000986	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Fluorouracil—colon cancer	9.16e-05	0.000984	CcSEcCtD
Nilotinib—Decreased appetite—Irinotecan—colon cancer	9.12e-05	0.00098	CcSEcCtD
Nilotinib—Eosinophilia—Methotrexate—colon cancer	9.1e-05	0.000978	CcSEcCtD
Nilotinib—ABCG2—liver—colon cancer	9.1e-05	0.00115	CbGeAlD
Nilotinib—Insomnia—Fluorouracil—colon cancer	9.09e-05	0.000977	CcSEcCtD
Nilotinib—CA4—lymph node—colon cancer	9.09e-05	0.00114	CbGeAlD
Nilotinib—Gastrointestinal disorder—Irinotecan—colon cancer	9.06e-05	0.000973	CcSEcCtD
Nilotinib—Fatigue—Irinotecan—colon cancer	9.05e-05	0.000972	CcSEcCtD
Nilotinib—Paraesthesia—Fluorouracil—colon cancer	9.02e-05	0.00097	CcSEcCtD
Nilotinib—Pancreatitis—Methotrexate—colon cancer	9.01e-05	0.000968	CcSEcCtD
Nilotinib—Pain—Irinotecan—colon cancer	8.97e-05	0.000964	CcSEcCtD
Nilotinib—Constipation—Irinotecan—colon cancer	8.97e-05	0.000964	CcSEcCtD
Nilotinib—Angiopathy—Capecitabine—colon cancer	8.97e-05	0.000964	CcSEcCtD
Nilotinib—Dyspnoea—Fluorouracil—colon cancer	8.96e-05	0.000963	CcSEcCtD
Nilotinib—Immune system disorder—Capecitabine—colon cancer	8.93e-05	0.000959	CcSEcCtD
Nilotinib—Mediastinal disorder—Capecitabine—colon cancer	8.91e-05	0.000957	CcSEcCtD
Nilotinib—Chills—Capecitabine—colon cancer	8.87e-05	0.000953	CcSEcCtD
Nilotinib—Dyspepsia—Fluorouracil—colon cancer	8.85e-05	0.00095	CcSEcCtD
Nilotinib—Arrhythmia—Capecitabine—colon cancer	8.83e-05	0.000949	CcSEcCtD
Nilotinib—Abdominal discomfort—Methotrexate—colon cancer	8.81e-05	0.000947	CcSEcCtD
Nilotinib—Gastrointestinal pain—Vincristine—colon cancer	8.81e-05	0.000947	CcSEcCtD
Nilotinib—Decreased appetite—Fluorouracil—colon cancer	8.74e-05	0.000939	CcSEcCtD
Nilotinib—Alopecia—Capecitabine—colon cancer	8.73e-05	0.000938	CcSEcCtD
Nilotinib—Pancytopenia—Methotrexate—colon cancer	8.73e-05	0.000938	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Fluorouracil—colon cancer	8.68e-05	0.000932	CcSEcCtD
Nilotinib—Mental disorder—Capecitabine—colon cancer	8.66e-05	0.00093	CcSEcCtD
Nilotinib—Feeling abnormal—Irinotecan—colon cancer	8.65e-05	0.000929	CcSEcCtD
Nilotinib—Malnutrition—Capecitabine—colon cancer	8.6e-05	0.000924	CcSEcCtD
Nilotinib—Erythema—Capecitabine—colon cancer	8.6e-05	0.000924	CcSEcCtD
Nilotinib—Neutropenia—Methotrexate—colon cancer	8.6e-05	0.000924	CcSEcCtD
Nilotinib—Dysuria—Methotrexate—colon cancer	8.6e-05	0.000924	CcSEcCtD
Nilotinib—Pain—Fluorouracil—colon cancer	8.59e-05	0.000923	CcSEcCtD
Nilotinib—Gastrointestinal pain—Irinotecan—colon cancer	8.58e-05	0.000922	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Methotrexate—colon cancer	8.54e-05	0.000918	CcSEcCtD
Nilotinib—Abdominal pain—Vincristine—colon cancer	8.52e-05	0.000915	CcSEcCtD
Nilotinib—Body temperature increased—Vincristine—colon cancer	8.52e-05	0.000915	CcSEcCtD
Nilotinib—CYP3A4—digestive system—colon cancer	8.51e-05	0.00107	CbGeAlD
Nilotinib—Flatulence—Capecitabine—colon cancer	8.48e-05	0.000911	CcSEcCtD
Nilotinib—Erectile dysfunction—Methotrexate—colon cancer	8.47e-05	0.00091	CcSEcCtD
Nilotinib—Dysgeusia—Capecitabine—colon cancer	8.43e-05	0.000905	CcSEcCtD
Nilotinib—CYP2B6—liver—colon cancer	8.39e-05	0.00106	CbGeAlD
Nilotinib—Photosensitivity reaction—Methotrexate—colon cancer	8.39e-05	0.000902	CcSEcCtD
Nilotinib—CYP2D6—digestive system—colon cancer	8.37e-05	0.00105	CbGeAlD
Nilotinib—Back pain—Capecitabine—colon cancer	8.32e-05	0.000894	CcSEcCtD
Nilotinib—CYP2C9—liver—colon cancer	8.31e-05	0.00105	CbGeAlD
Nilotinib—Body temperature increased—Irinotecan—colon cancer	8.29e-05	0.000891	CcSEcCtD
Nilotinib—Abdominal pain—Irinotecan—colon cancer	8.29e-05	0.000891	CcSEcCtD
Nilotinib—Feeling abnormal—Fluorouracil—colon cancer	8.28e-05	0.00089	CcSEcCtD
Nilotinib—Muscle spasms—Capecitabine—colon cancer	8.27e-05	0.000889	CcSEcCtD
Nilotinib—Pneumonia—Methotrexate—colon cancer	8.24e-05	0.000886	CcSEcCtD
Nilotinib—Infestation—Methotrexate—colon cancer	8.2e-05	0.000881	CcSEcCtD
Nilotinib—Infestation NOS—Methotrexate—colon cancer	8.2e-05	0.000881	CcSEcCtD
Nilotinib—Vision blurred—Capecitabine—colon cancer	8.11e-05	0.000871	CcSEcCtD
Nilotinib—Tremor—Capecitabine—colon cancer	8.06e-05	0.000866	CcSEcCtD
Nilotinib—Renal failure—Methotrexate—colon cancer	8.06e-05	0.000866	CcSEcCtD
Nilotinib—Stomatitis—Methotrexate—colon cancer	7.99e-05	0.000858	CcSEcCtD
Nilotinib—Ill-defined disorder—Capecitabine—colon cancer	7.98e-05	0.000858	CcSEcCtD
Nilotinib—Urticaria—Fluorouracil—colon cancer	7.98e-05	0.000858	CcSEcCtD
Nilotinib—Conjunctivitis—Methotrexate—colon cancer	7.97e-05	0.000856	CcSEcCtD
Nilotinib—Anaemia—Capecitabine—colon cancer	7.95e-05	0.000854	CcSEcCtD
Nilotinib—Body temperature increased—Fluorouracil—colon cancer	7.94e-05	0.000854	CcSEcCtD
Nilotinib—Hypersensitivity—Vincristine—colon cancer	7.94e-05	0.000853	CcSEcCtD
Nilotinib—ABCB1—epithelium—colon cancer	7.92e-05	0.000997	CbGeAlD
Nilotinib—Haematuria—Methotrexate—colon cancer	7.82e-05	0.00084	CcSEcCtD
Nilotinib—Malaise—Capecitabine—colon cancer	7.76e-05	0.000834	CcSEcCtD
Nilotinib—Hepatobiliary disease—Methotrexate—colon cancer	7.75e-05	0.000833	CcSEcCtD
Nilotinib—Epistaxis—Methotrexate—colon cancer	7.73e-05	0.000831	CcSEcCtD
Nilotinib—Vertigo—Capecitabine—colon cancer	7.73e-05	0.000831	CcSEcCtD
Nilotinib—Hypersensitivity—Irinotecan—colon cancer	7.73e-05	0.000831	CcSEcCtD
Nilotinib—Asthenia—Vincristine—colon cancer	7.73e-05	0.000831	CcSEcCtD
Nilotinib—Syncope—Capecitabine—colon cancer	7.72e-05	0.000829	CcSEcCtD
Nilotinib—Leukopenia—Capecitabine—colon cancer	7.7e-05	0.000828	CcSEcCtD
Nilotinib—Palpitations—Capecitabine—colon cancer	7.6e-05	0.000817	CcSEcCtD
Nilotinib—Loss of consciousness—Capecitabine—colon cancer	7.56e-05	0.000813	CcSEcCtD
Nilotinib—CA2—lymph node—colon cancer	7.53e-05	0.000949	CbGeAlD
Nilotinib—Asthenia—Irinotecan—colon cancer	7.53e-05	0.000809	CcSEcCtD
Nilotinib—Cough—Capecitabine—colon cancer	7.51e-05	0.000807	CcSEcCtD
Nilotinib—Hypertension—Capecitabine—colon cancer	7.43e-05	0.000798	CcSEcCtD
Nilotinib—Hypersensitivity—Fluorouracil—colon cancer	7.4e-05	0.000795	CcSEcCtD
Nilotinib—Haemoglobin—Methotrexate—colon cancer	7.4e-05	0.000795	CcSEcCtD
Nilotinib—Diarrhoea—Vincristine—colon cancer	7.37e-05	0.000792	CcSEcCtD
Nilotinib—Hepatitis—Methotrexate—colon cancer	7.36e-05	0.000791	CcSEcCtD
Nilotinib—Haemorrhage—Methotrexate—colon cancer	7.36e-05	0.000791	CcSEcCtD
Nilotinib—ABCB1—renal system—colon cancer	7.34e-05	0.000925	CbGeAlD
Nilotinib—Chest pain—Capecitabine—colon cancer	7.33e-05	0.000787	CcSEcCtD
Nilotinib—Arthralgia—Capecitabine—colon cancer	7.33e-05	0.000787	CcSEcCtD
Nilotinib—Myalgia—Capecitabine—colon cancer	7.33e-05	0.000787	CcSEcCtD
Nilotinib—Pharyngitis—Methotrexate—colon cancer	7.3e-05	0.000785	CcSEcCtD
Nilotinib—Anxiety—Capecitabine—colon cancer	7.3e-05	0.000784	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	7.28e-05	0.000782	CcSEcCtD
Nilotinib—Urinary tract disorder—Methotrexate—colon cancer	7.27e-05	0.000781	CcSEcCtD
Nilotinib—Discomfort—Capecitabine—colon cancer	7.24e-05	0.000778	CcSEcCtD
Nilotinib—Urethral disorder—Methotrexate—colon cancer	7.21e-05	0.000775	CcSEcCtD
Nilotinib—Diarrhoea—Irinotecan—colon cancer	7.18e-05	0.000771	CcSEcCtD
Nilotinib—Dry mouth—Capecitabine—colon cancer	7.16e-05	0.00077	CcSEcCtD
Nilotinib—Dizziness—Vincristine—colon cancer	7.12e-05	0.000765	CcSEcCtD
Nilotinib—Pruritus—Fluorouracil—colon cancer	7.11e-05	0.000764	CcSEcCtD
Nilotinib—Visual impairment—Methotrexate—colon cancer	7.09e-05	0.000762	CcSEcCtD
Nilotinib—Confusional state—Capecitabine—colon cancer	7.08e-05	0.000761	CcSEcCtD
Nilotinib—Oedema—Capecitabine—colon cancer	7.02e-05	0.000755	CcSEcCtD
Nilotinib—Infection—Capecitabine—colon cancer	6.98e-05	0.00075	CcSEcCtD
Nilotinib—ABCG2—lymph node—colon cancer	6.98e-05	0.000879	CbGeAlD
Nilotinib—Erythema multiforme—Methotrexate—colon cancer	6.96e-05	0.000747	CcSEcCtD
Nilotinib—Dizziness—Irinotecan—colon cancer	6.94e-05	0.000745	CcSEcCtD
Nilotinib—Shock—Capecitabine—colon cancer	6.91e-05	0.000742	CcSEcCtD
Nilotinib—Nervous system disorder—Capecitabine—colon cancer	6.89e-05	0.00074	CcSEcCtD
Nilotinib—Eye disorder—Methotrexate—colon cancer	6.88e-05	0.000739	CcSEcCtD
Nilotinib—Diarrhoea—Fluorouracil—colon cancer	6.88e-05	0.000739	CcSEcCtD
Nilotinib—Thrombocytopenia—Capecitabine—colon cancer	6.88e-05	0.000739	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—colon cancer	6.86e-05	0.000737	CcSEcCtD
Nilotinib—Tachycardia—Capecitabine—colon cancer	6.85e-05	0.000736	CcSEcCtD
Nilotinib—Vomiting—Vincristine—colon cancer	6.85e-05	0.000736	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—colon cancer	6.83e-05	0.000734	CcSEcCtD
Nilotinib—Skin disorder—Capecitabine—colon cancer	6.82e-05	0.000733	CcSEcCtD
Nilotinib—Rash—Vincristine—colon cancer	6.79e-05	0.00073	CcSEcCtD
Nilotinib—Hyperhidrosis—Capecitabine—colon cancer	6.79e-05	0.000729	CcSEcCtD
Nilotinib—Dermatitis—Vincristine—colon cancer	6.79e-05	0.000729	CcSEcCtD
Nilotinib—Headache—Vincristine—colon cancer	6.75e-05	0.000725	CcSEcCtD
Nilotinib—Anorexia—Capecitabine—colon cancer	6.69e-05	0.000719	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—colon cancer	6.68e-05	0.000717	CcSEcCtD
Nilotinib—Vomiting—Irinotecan—colon cancer	6.67e-05	0.000717	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—colon cancer	6.65e-05	0.000714	CcSEcCtD
Nilotinib—Dizziness—Fluorouracil—colon cancer	6.65e-05	0.000714	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—colon cancer	6.63e-05	0.000713	CcSEcCtD
Nilotinib—Rash—Irinotecan—colon cancer	6.62e-05	0.000711	CcSEcCtD
Nilotinib—Dermatitis—Irinotecan—colon cancer	6.61e-05	0.00071	CcSEcCtD
Nilotinib—Chills—Methotrexate—colon cancer	6.6e-05	0.000709	CcSEcCtD
Nilotinib—Headache—Irinotecan—colon cancer	6.57e-05	0.000706	CcSEcCtD
Nilotinib—Hypotension—Capecitabine—colon cancer	6.56e-05	0.000705	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—colon cancer	6.5e-05	0.000699	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—colon cancer	6.45e-05	0.000693	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—colon cancer	6.41e-05	0.000688	CcSEcCtD
Nilotinib—Erythema—Methotrexate—colon cancer	6.41e-05	0.000688	CcSEcCtD
Nilotinib—Nausea—Vincristine—colon cancer	6.4e-05	0.000688	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Capecitabine—colon cancer	6.4e-05	0.000687	CcSEcCtD
Nilotinib—Vomiting—Fluorouracil—colon cancer	6.39e-05	0.000686	CcSEcCtD
Nilotinib—Insomnia—Capecitabine—colon cancer	6.35e-05	0.000682	CcSEcCtD
Nilotinib—CYP3A4—liver—colon cancer	6.34e-05	0.000798	CbGeAlD
Nilotinib—Rash—Fluorouracil—colon cancer	6.34e-05	0.000681	CcSEcCtD
Nilotinib—Dermatitis—Fluorouracil—colon cancer	6.33e-05	0.00068	CcSEcCtD
Nilotinib—Paraesthesia—Capecitabine—colon cancer	6.31e-05	0.000678	CcSEcCtD
Nilotinib—Headache—Fluorouracil—colon cancer	6.3e-05	0.000676	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—colon cancer	6.27e-05	0.000674	CcSEcCtD
Nilotinib—Dyspnoea—Capecitabine—colon cancer	6.26e-05	0.000673	CcSEcCtD
Nilotinib—CYP2D6—liver—colon cancer	6.24e-05	0.000786	CbGeAlD
Nilotinib—Nausea—Irinotecan—colon cancer	6.23e-05	0.00067	CcSEcCtD
Nilotinib—Back pain—Methotrexate—colon cancer	6.2e-05	0.000666	CcSEcCtD
Nilotinib—Dyspepsia—Capecitabine—colon cancer	6.18e-05	0.000664	CcSEcCtD
Nilotinib—Decreased appetite—Capecitabine—colon cancer	6.1e-05	0.000656	CcSEcCtD
Nilotinib—ABCB1—lymphoid tissue—colon cancer	6.1e-05	0.000768	CbGeAlD
Nilotinib—Gastrointestinal disorder—Capecitabine—colon cancer	6.06e-05	0.000651	CcSEcCtD
Nilotinib—Fatigue—Capecitabine—colon cancer	6.05e-05	0.00065	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—colon cancer	6.04e-05	0.000649	CcSEcCtD
Nilotinib—ABCB1—digestive system—colon cancer	6.02e-05	0.000759	CbGeAlD
Nilotinib—Pain—Capecitabine—colon cancer	6.01e-05	0.000645	CcSEcCtD
Nilotinib—Constipation—Capecitabine—colon cancer	6.01e-05	0.000645	CcSEcCtD
Nilotinib—Nausea—Fluorouracil—colon cancer	5.97e-05	0.000641	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—colon cancer	5.94e-05	0.000639	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—colon cancer	5.92e-05	0.000636	CcSEcCtD
Nilotinib—Feeling abnormal—Capecitabine—colon cancer	5.79e-05	0.000622	CcSEcCtD
Nilotinib—Malaise—Methotrexate—colon cancer	5.78e-05	0.000621	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—colon cancer	5.75e-05	0.000618	CcSEcCtD
Nilotinib—Gastrointestinal pain—Capecitabine—colon cancer	5.74e-05	0.000617	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—colon cancer	5.73e-05	0.000616	CcSEcCtD
Nilotinib—Cough—Methotrexate—colon cancer	5.59e-05	0.000601	CcSEcCtD
Nilotinib—Urticaria—Capecitabine—colon cancer	5.58e-05	0.000599	CcSEcCtD
Nilotinib—ABCB1—bone marrow—colon cancer	5.55e-05	0.000699	CbGeAlD
Nilotinib—Abdominal pain—Capecitabine—colon cancer	5.55e-05	0.000596	CcSEcCtD
Nilotinib—Body temperature increased—Capecitabine—colon cancer	5.55e-05	0.000596	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—colon cancer	5.45e-05	0.000586	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—colon cancer	5.45e-05	0.000586	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—colon cancer	5.45e-05	0.000586	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	5.42e-05	0.000582	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—colon cancer	5.39e-05	0.000579	CcSEcCtD
Nilotinib—ABCB1—vagina—colon cancer	5.32e-05	0.00067	CbGeAlD
Nilotinib—Confusional state—Methotrexate—colon cancer	5.27e-05	0.000566	CcSEcCtD
Nilotinib—Infection—Methotrexate—colon cancer	5.19e-05	0.000558	CcSEcCtD
Nilotinib—Hypersensitivity—Capecitabine—colon cancer	5.17e-05	0.000556	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—colon cancer	5.13e-05	0.000551	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—colon cancer	5.12e-05	0.00055	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—colon cancer	5.08e-05	0.000546	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—colon cancer	5.05e-05	0.000543	CcSEcCtD
Nilotinib—Asthenia—Capecitabine—colon cancer	5.04e-05	0.000541	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—colon cancer	4.98e-05	0.000535	CcSEcCtD
Nilotinib—Pruritus—Capecitabine—colon cancer	4.97e-05	0.000534	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—colon cancer	4.88e-05	0.000525	CcSEcCtD
Nilotinib—Diarrhoea—Capecitabine—colon cancer	4.8e-05	0.000516	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—colon cancer	4.76e-05	0.000512	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—colon cancer	4.73e-05	0.000508	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—colon cancer	4.69e-05	0.000504	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—colon cancer	4.66e-05	0.000501	CcSEcCtD
Nilotinib—Dizziness—Capecitabine—colon cancer	4.64e-05	0.000499	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—colon cancer	4.6e-05	0.000494	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—colon cancer	4.54e-05	0.000488	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—colon cancer	4.51e-05	0.000485	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—colon cancer	4.51e-05	0.000484	CcSEcCtD
Nilotinib—ABCB1—liver—colon cancer	4.49e-05	0.000565	CbGeAlD
Nilotinib—Pain—Methotrexate—colon cancer	4.47e-05	0.00048	CcSEcCtD
Nilotinib—Vomiting—Capecitabine—colon cancer	4.47e-05	0.00048	CcSEcCtD
Nilotinib—Rash—Capecitabine—colon cancer	4.43e-05	0.000476	CcSEcCtD
Nilotinib—Dermatitis—Capecitabine—colon cancer	4.42e-05	0.000475	CcSEcCtD
Nilotinib—Headache—Capecitabine—colon cancer	4.4e-05	0.000473	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—colon cancer	4.31e-05	0.000463	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—colon cancer	4.27e-05	0.000459	CcSEcCtD
Nilotinib—Nausea—Capecitabine—colon cancer	4.17e-05	0.000448	CcSEcCtD
Nilotinib—Urticaria—Methotrexate—colon cancer	4.15e-05	0.000446	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—colon cancer	4.13e-05	0.000444	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—colon cancer	4.13e-05	0.000444	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—colon cancer	3.85e-05	0.000414	CcSEcCtD
Nilotinib—Asthenia—Methotrexate—colon cancer	3.75e-05	0.000403	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—colon cancer	3.7e-05	0.000397	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—colon cancer	3.58e-05	0.000384	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—colon cancer	3.46e-05	0.000371	CcSEcCtD
Nilotinib—ABCB1—lymph node—colon cancer	3.44e-05	0.000433	CbGeAlD
Nilotinib—Vomiting—Methotrexate—colon cancer	3.32e-05	0.000357	CcSEcCtD
Nilotinib—Rash—Methotrexate—colon cancer	3.3e-05	0.000354	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—colon cancer	3.29e-05	0.000354	CcSEcCtD
Nilotinib—Headache—Methotrexate—colon cancer	3.27e-05	0.000352	CcSEcCtD
Nilotinib—Nausea—Methotrexate—colon cancer	3.11e-05	0.000334	CcSEcCtD
Nilotinib—LCK—Immune System—CDKN1A—colon cancer	2.15e-06	1.6e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EP300—colon cancer	2.14e-06	1.59e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.13e-06	1.59e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EGFR—colon cancer	2.13e-06	1.58e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EP300—colon cancer	2.12e-06	1.58e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—AKT1—colon cancer	2.12e-06	1.58e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EGFR—colon cancer	2.12e-06	1.58e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KRAS—colon cancer	2.1e-06	1.57e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCND1—colon cancer	2.1e-06	1.56e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—APC—colon cancer	2.09e-06	1.56e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—PIK3CA—colon cancer	2.09e-06	1.56e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.09e-06	1.55e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ABCB1—colon cancer	2.09e-06	1.55e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—SRC—colon cancer	2.08e-06	1.55e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AKT1—colon cancer	2.08e-06	1.55e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CTNNB1—colon cancer	2.08e-06	1.55e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—HRAS—colon cancer	2.07e-06	1.54e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—SRC—colon cancer	2.06e-06	1.54e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KRAS—colon cancer	2.06e-06	1.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KRAS—colon cancer	2.05e-06	1.53e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TYMS—colon cancer	2.05e-06	1.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MYC—colon cancer	2.05e-06	1.53e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MYC—colon cancer	2.05e-06	1.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TGFB1—colon cancer	2.04e-06	1.52e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—HRAS—colon cancer	2.04e-06	1.52e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EP300—colon cancer	2.04e-06	1.52e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CASP3—colon cancer	2.04e-06	1.52e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—PIK3CA—colon cancer	2.04e-06	1.52e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—AKT1—colon cancer	2.04e-06	1.52e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CTNNB1—colon cancer	2.03e-06	1.51e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CDKN1A—colon cancer	2.03e-06	1.51e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—colon cancer	2.03e-06	1.51e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—colon cancer	2.02e-06	1.5e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—colon cancer	2.01e-06	1.5e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—KRAS—colon cancer	2.01e-06	1.5e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—colon cancer	2e-06	1.49e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NRAS—colon cancer	2e-06	1.49e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—AKT1—colon cancer	2e-06	1.49e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KRAS—colon cancer	2e-06	1.49e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—AKT1—colon cancer	1.99e-06	1.48e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PIK3CA—colon cancer	1.99e-06	1.48e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—SRC—colon cancer	1.99e-06	1.48e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCND1—colon cancer	1.99e-06	1.48e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NRAS—colon cancer	1.99e-06	1.48e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CDKN1A—colon cancer	1.98e-06	1.48e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—BRAF—colon cancer	1.97e-06	1.46e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CTNNB1—colon cancer	1.97e-06	1.46e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HRAS—colon cancer	1.94e-06	1.44e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EP300—colon cancer	1.93e-06	1.44e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PIK3CA—colon cancer	1.93e-06	1.44e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—colon cancer	1.92e-06	1.43e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CDKN1A—colon cancer	1.92e-06	1.43e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NRAS—colon cancer	1.91e-06	1.42e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KRAS—colon cancer	1.9e-06	1.42e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KRAS—colon cancer	1.89e-06	1.41e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PIK3CA—colon cancer	1.89e-06	1.41e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—HRAS—colon cancer	1.89e-06	1.41e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EP300—colon cancer	1.89e-06	1.41e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PIK3CA—colon cancer	1.88e-06	1.4e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SRC—colon cancer	1.88e-06	1.4e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—colon cancer	1.87e-06	1.39e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—colon cancer	1.86e-06	1.39e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—colon cancer	1.85e-06	1.38e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—PIK3CA—colon cancer	1.85e-06	1.37e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—colon cancer	1.84e-06	1.37e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—colon cancer	1.84e-06	1.37e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HRAS—colon cancer	1.84e-06	1.37e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CASP3—colon cancer	1.84e-06	1.37e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PIK3CA—colon cancer	1.84e-06	1.37e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—SRC—colon cancer	1.84e-06	1.37e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—colon cancer	1.83e-06	1.36e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—colon cancer	1.83e-06	1.36e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—colon cancer	1.83e-06	1.36e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—colon cancer	1.83e-06	1.36e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EP300—colon cancer	1.83e-06	1.36e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—colon cancer	1.83e-06	1.36e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—colon cancer	1.81e-06	1.35e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NRAS—colon cancer	1.81e-06	1.35e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—colon cancer	1.81e-06	1.34e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—EP300—colon cancer	1.8e-06	1.34e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CASP3—colon cancer	1.8e-06	1.34e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—colon cancer	1.79e-06	1.33e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—colon cancer	1.79e-06	1.33e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TYMS—colon cancer	1.79e-06	1.33e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SRC—colon cancer	1.78e-06	1.32e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CTNNB1—colon cancer	1.77e-06	1.32e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NRAS—colon cancer	1.77e-06	1.31e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—colon cancer	1.75e-06	1.3e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—colon cancer	1.75e-06	1.3e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PIK3CA—colon cancer	1.75e-06	1.3e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—colon cancer	1.74e-06	1.3e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—colon cancer	1.74e-06	1.3e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PIK3CA—colon cancer	1.74e-06	1.3e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.74e-06	1.29e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CTNNB1—colon cancer	1.74e-06	1.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—colon cancer	1.73e-06	1.29e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1A—colon cancer	1.73e-06	1.29e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—colon cancer	1.72e-06	1.28e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—colon cancer	1.72e-06	1.28e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCB1—colon cancer	1.71e-06	1.28e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NRAS—colon cancer	1.71e-06	1.27e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—colon cancer	1.71e-06	1.27e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—colon cancer	1.71e-06	1.27e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—colon cancer	1.71e-06	1.27e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—colon cancer	1.71e-06	1.27e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCB1—colon cancer	1.7e-06	1.27e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—colon cancer	1.7e-06	1.26e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1A—colon cancer	1.69e-06	1.26e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TYMS—colon cancer	1.68e-06	1.25e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—colon cancer	1.68e-06	1.25e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—colon cancer	1.68e-06	1.25e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TYMS—colon cancer	1.67e-06	1.24e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—colon cancer	1.67e-06	1.24e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—colon cancer	1.66e-06	1.24e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EP300—colon cancer	1.65e-06	1.23e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—colon cancer	1.65e-06	1.23e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—colon cancer	1.65e-06	1.23e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—colon cancer	1.64e-06	1.22e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CTNNB1—colon cancer	1.64e-06	1.22e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—colon cancer	1.64e-06	1.22e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—colon cancer	1.62e-06	1.21e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—colon cancer	1.62e-06	1.2e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EP300—colon cancer	1.61e-06	1.2e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—colon cancer	1.61e-06	1.2e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—colon cancer	1.61e-06	1.2e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1A—colon cancer	1.61e-06	1.2e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SRC—colon cancer	1.6e-06	1.19e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—colon cancer	1.59e-06	1.19e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—colon cancer	1.59e-06	1.18e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—colon cancer	1.58e-06	1.18e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.58e-06	1.18e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—colon cancer	1.58e-06	1.17e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—colon cancer	1.57e-06	1.17e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SRC—colon cancer	1.57e-06	1.17e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—colon cancer	1.56e-06	1.16e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—colon cancer	1.56e-06	1.16e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—colon cancer	1.56e-06	1.16e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—colon cancer	1.54e-06	1.15e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NRAS—colon cancer	1.54e-06	1.15e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—colon cancer	1.54e-06	1.15e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—colon cancer	1.53e-06	1.14e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—EP300—colon cancer	1.53e-06	1.14e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EP300—colon cancer	1.53e-06	1.14e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—colon cancer	1.53e-06	1.14e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—colon cancer	1.52e-06	1.13e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—colon cancer	1.52e-06	1.13e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—colon cancer	1.51e-06	1.13e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NRAS—colon cancer	1.51e-06	1.12e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—colon cancer	1.51e-06	1.12e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—colon cancer	1.5e-06	1.12e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SRC—colon cancer	1.49e-06	1.11e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—colon cancer	1.48e-06	1.1e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—colon cancer	1.47e-06	1.1e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—colon cancer	1.47e-06	1.09e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—colon cancer	1.45e-06	1.08e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—colon cancer	1.45e-06	1.08e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—colon cancer	1.45e-06	1.08e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—colon cancer	1.44e-06	1.07e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—colon cancer	1.44e-06	1.07e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—colon cancer	1.43e-06	1.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NRAS—colon cancer	1.43e-06	1.06e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—colon cancer	1.43e-06	1.06e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—colon cancer	1.43e-06	1.06e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CTNNB1—colon cancer	1.42e-06	1.06e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—colon cancer	1.42e-06	1.06e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—colon cancer	1.42e-06	1.06e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—colon cancer	1.41e-06	1.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—colon cancer	1.4e-06	1.05e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—colon cancer	1.4e-06	1.04e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—colon cancer	1.4e-06	1.04e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—colon cancer	1.4e-06	1.04e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1A—colon cancer	1.39e-06	1.03e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—colon cancer	1.38e-06	1.03e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—colon cancer	1.37e-06	1.02e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—colon cancer	1.35e-06	1.01e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—colon cancer	1.35e-06	1e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—colon cancer	1.34e-06	9.94e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—colon cancer	1.33e-06	9.92e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—colon cancer	1.33e-06	9.89e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—colon cancer	1.33e-06	9.87e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—colon cancer	1.32e-06	9.84e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EP300—colon cancer	1.32e-06	9.84e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—colon cancer	1.31e-06	9.74e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—colon cancer	1.3e-06	9.7e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—colon cancer	1.3e-06	9.67e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—colon cancer	1.29e-06	9.64e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—colon cancer	1.29e-06	9.62e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SRC—colon cancer	1.29e-06	9.57e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.28e-06	9.56e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—colon cancer	1.28e-06	9.55e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—colon cancer	1.27e-06	9.42e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—colon cancer	1.25e-06	9.32e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—colon cancer	1.25e-06	9.32e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRAS—colon cancer	1.24e-06	9.21e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—colon cancer	1.24e-06	9.2e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—colon cancer	1.23e-06	9.16e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—colon cancer	1.22e-06	9.07e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—colon cancer	1.19e-06	8.88e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—colon cancer	1.19e-06	8.88e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—colon cancer	1.18e-06	8.8e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—colon cancer	1.18e-06	8.78e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—colon cancer	1.17e-06	8.69e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—colon cancer	1.15e-06	8.59e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—colon cancer	1.15e-06	8.58e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—colon cancer	1.15e-06	8.55e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—colon cancer	1.14e-06	8.51e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—colon cancer	1.14e-06	8.49e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—colon cancer	1.13e-06	8.43e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—colon cancer	1.13e-06	8.42e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—colon cancer	1.13e-06	8.39e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—colon cancer	1.13e-06	8.39e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—EP300—colon cancer	1.12e-06	8.36e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCB1—colon cancer	1.12e-06	8.34e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—colon cancer	1.1e-06	8.23e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—colon cancer	1.1e-06	8.22e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TYMS—colon cancer	1.1e-06	8.19e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—colon cancer	1.09e-06	8.14e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—colon cancer	1.09e-06	8.12e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—colon cancer	1.06e-06	7.92e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—colon cancer	1.05e-06	7.79e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—colon cancer	9.96e-07	7.41e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—colon cancer	9.95e-07	7.41e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—colon cancer	9.78e-07	7.28e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—colon cancer	9.75e-07	7.26e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—EP300—colon cancer	9.5e-07	7.08e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—colon cancer	9.46e-07	7.04e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—colon cancer	9.38e-07	6.98e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—colon cancer	9.3e-07	6.92e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—colon cancer	9.25e-07	6.89e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—colon cancer	9.24e-07	6.88e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—colon cancer	9.05e-07	6.73e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—colon cancer	8.3e-07	6.18e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—EP300—colon cancer	8.28e-07	6.16e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—colon cancer	7.99e-07	5.95e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—EP300—colon cancer	7.8e-07	5.81e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—colon cancer	7.8e-07	5.8e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—EP300—colon cancer	7.74e-07	5.76e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—colon cancer	7.03e-07	5.23e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—colon cancer	6.78e-07	5.05e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—colon cancer	6.13e-07	4.57e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—colon cancer	6.13e-07	4.56e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—colon cancer	5.77e-07	4.3e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—colon cancer	5.74e-07	4.28e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—colon cancer	5.72e-07	4.26e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—EP300—colon cancer	5.1e-07	3.8e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—colon cancer	5e-07	3.72e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—colon cancer	4.72e-07	3.51e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—colon cancer	4.67e-07	3.48e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—colon cancer	3.77e-07	2.81e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—colon cancer	3.08e-07	2.29e-06	CbGpPWpGaD
